The increasing prevalence of chronic and mental disorder is a key factor expected to enable growth in the global schizophrenia drugs market, says Fortune Business Insights in a report, titled “Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026.” The global schizophrenia drugs market was valued at USD 6.75 Billion in 2018 and is projected to reach USD 9.48 Billion by 2026, exhibiting a CAGR of 4.3% during the forecast period.
According to the report, the global market on the basis of by therapeutic class is segmented into the second generation, third generation and others. The second-generation segment is expected to hold a major share in the schizophrenia drugs market owing to its greater efficacy and substantially lesser adverse reactions with it. In addition, the first generation segment will witness slower growth due to the side effects associated with first-generation drugs.
Some of the Leading Players Operating In report:
- Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Janssen Pharmaceuticals, Inc.
- Eli Lilly and Company
- Vanda Pharmaceuticals Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Alkermes plc
- Bristol-Myers Squibb Company
Rising Awareness About Mental Disorders Will Boost Growth
According to Fortune Business Insights, the increasing cases of mental disorders such as schizophrenia will uplift the global market shares. The surge in medical interventions for the treatment of major mental disorders will enable growth in the globalmarket during the forecast period. Furthermore, the rising emphasis on mental illness and mental health in emerging nations will boost the global schizophrenia drugs market revenue during the forecast period. Moreover, the increasing efficacy and safety features of treatment for schizophrenia will fuel demand among patients which,will in turn, accelerate the growth of the global schizophrenia drugs.
Table of Content
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1. Increasing Adoption of Long-Acting Injectable (LAIs) as a Form of Treatment
4.2. Prevalence of Schizophrenia Disorders by Key Regions
4.3. New Product Launches
4.4. Pipeline Analysis
4.5. Regulatory Scenario By Key Regions
4.6. Analysis of First-Generation Antipsychotics versus Second & Third Generation Antipsychotics
4.7. Overview of R&D Initiatives in Schizophrenia Treatment
- Global Schizophrenia Drugs Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Therapeutic Class
5.2.1. Third Generation Antipsychotics
More Trending Topics from Fortune Business Insights: